Merck KGaA
🇩🇪 Deutschland aktiv
Deutsches Pharma- und Chemieunternehmen mit Sitz in Darmstadt. Aktiv in Biopharmazeutika, Life-Science-Technologien sowie elektronischen Materialien für Halbleiter- und Displayindustrie. Nicht zu verwechseln mit dem US-Unternehmen Merck & Co.
Vertretung
Kanzleien und Patentanwälte, die Merck KGaA in unserer Datenbank vertreten.
Mit Komplettzugriff sehen Sie die vollständige Vertretung inkl. aller Kanzleien und Patentanwälte.
Komplettzugriff erhaltenMit Komplettzugriff sehen Sie die vollständige Vertretung inkl. aller Kanzleien und Patentanwälte.
Komplettzugriff erhaltenPatentanmelder folgen
Erhalten Sie wöchentlich eine E-Mail, sobald neue Patente von Merck KGaA veröffentlicht werden.
Erfolgreich angemeldet!
Sie erhalten ab sofort wöchentliche Berichte zu neuen Patenten von Merck KGaA.
Patente
5.277 gesamt| Patent | |||
|---|---|---|---|
|
10.06.2026
Aminolipide für Lipidbasierte Abgabesysteme
|
|||
|
Zusammenfassung
The invention relates to ionizable cationic amino lipids and lipid-based delivery systems, such as lipid particles comprising ionizable cationic amino lipids of the invention and their use for delivering a payload into a cell. |
|||
|
27.05.2026
Formulierungen zur Selektiven Ablagerung
|
|||
|
Zusammenfassung
The disclosed and claimed subject matter relates to formulations that include (i) one or more alkynes in combination with (ii) one or more tertiary alcohols as well as their use for enhanced passivation of metallic substrates. |
|||
|
27.05.2026
Flüssigkristallines Medium
|
|||
|
Zusammenfassung
The present invention relates to liquid-crystalline (LC) media or LC materials and to energy efficient liquid-crystal displays (LCDs) containing these media, especially to gaming displays and AR/VR headsets addressed by an active matrix and in particular to LC displays of the TN, PS-TN, STN, TN-TFT, OCB, IPS, PS-IPS, FFS, HB-FFS, XB-FFS, PS-FFS, SA-HB-FFS, SA-XB-FFS, polymer stabilised SA-HB-FFS, polymer stabilised SA-XB-FFS, positive VA or positive PS-VA type. |
|||
|
13.05.2026
Beschichtungslösungen mit Verbesserter Deck- und Weisswirkung
|
|||
|
Status
Angemeldet am 08.11.2024
Anhängig
Vertretung
Merck Patent Association
Zusammenfassung
The invention relates to coating solutions comprising a polyol, a polymer, and a solvent, wherein the polyol is mannitol or xylitol and the polymer is an aqueous soluble polymer or a cellulose based polymer, and the use of said coating solutions in the coating of medicaments. The invention further relates to a method for coating a medicament and the use of mannitol in a coating solution for medicaments. |
|||
|
13.05.2026
Flüssigkristallines Medium und Elektronisches Bauelement
|
|||
|
Zusammenfassung
The present invention relates to a liquid crystal medium and liquid crystal material comprising a) one or more compounds of formula I and one or more compounds of the formula T:in which the occurring groups and parameters have the meanings defined in claim 1, and to an electronic component comprising said LC medium, operable in the visible (VIS), infrared (IR) or microwave region of the electromagnetic spectrum. The invention further relates to the use of said LC medium in the IR, VIS or microwave region and to devices comprising said electronic component. |
|||
|
13.05.2026
Polymerisierbares Lc-Material und Polymerfolie
|
|||
|
Zusammenfassung
The instant invention relates to an optical component and a electro optical devices comprising the optical component. The instant invention further relates to a cholesteric polymerizable liquid crystalline (LC) material preferably utilized in an optical component in accordance with the present invention, to a process for the production of the cholesteric polymerizable LC material, to a process to convert the cholesteric polymerizable material into a polymer film, a polymer film obtainable from the cholesteric polymerizable LC material, the use of the polymer films in an optical component or device comprising a polymer film in accordance with the invention. |
|||
|
06.05.2026
Pharmazeutische Zusammensetzung mit einem Glp-1-Analogon und einem Anorganischen Mesoporösen Material
|
|||
|
Zusammenfassung
The present invention relates to pharmaceutical compositions comprising a therapeutic peptide having a molecular weight between 1 kDa and 100 kDa dispersed in an inorganic mesoporous material, said inorganic mesoporous material being in particular mesoporous silica. |
|||
|
29.04.2026
Ternäre Systeme mit Verbesserter Wirkstoffbeladungskapazität, Physikalischer Stabilität und Ausfällungshemmung
Medizintechnik & Gesundheit
|
|||
|
Zusammenfassung
The invention relates to a pharmaceutical composition comprising an active pharmaceutical ingredient (API), a carrier polymer, and tryptophan; as well as to a pharmaceutical composition according to the invention for use as a medicament. The invention further relates to a method for producing a pharmaceutical composition comprising the steps of a) mixing an API and a carrier polymer, and b) adding tryptophan. |
|||
|
29.04.2026
Flüssigkristallines Medium
Farben, Klebstoffe & Brennstoffe
|
|||
|
Zusammenfassung
The present invention relates to a liquid-crystal (LC) material as defined in claim 1, preferably having negative dielectric anisotropy and to the use thereof for optical, electro-optical and electronic purposes, such as for example in energy efficient LC displays, in particular displays of the PS-VA type. |
|||
|
15.04.2026
Anti-CEACAM5-Antikörper und Konjugate und Verwendungen davon
|
|||
|
Zusammenfassung
The invention provides antibodies which bind human CEACAM5 protein, as well as isolated nucleic acids and host cells comprising a sequence encoding said antibodies. The invention also provides immunoconjugates comprising said antibodies linked to a growth-inhibitory agent, and pharmaceutical compositions comprising antibodies or immunoconjugates of the invention. The invention also provides use of the antibodies, immunoconjugates and pharmaceutical compositions of the invention for the treatment of cancer or for diagnostic purposes. |
|||